Typical GLP tolerance and side effect profile These efficacy results approach those seen with weekly injectable formulations , even though oral delivery historically posed challenges due to absorption limitations in the gut
The most common side effects in the trial included: Nausea (about 29 to 42 percent of participants, depending on the dose) Diarrhea (25 to 34 percent) Constipation (24 to 26 percent) Vomiting (11 to 25 percent) Upper respiratory tract infection (12 to 14 percent) These side effects are consistent with other injectable weight loss medications, according to Siegel
ROR = 1.28, 95% CI = 1.191.38), eating disorder ( n = 289
First - paraphrasing Andy Grove - it pays to be paranoid
Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death
The space is calm, the staff are warm and professional, and I never felt rushed